A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
Clinical trial NCT03783442 · COMPLETED
Trial details
- NCT number
- NCT03783442
- Sponsor
- BeiGene
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-11
- Primary completion
- 2022-02-28
- Enrollment
- 649
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.